Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

An ADR is created when a bank buys shares of a foreign company outside the United States and issues a security representing shares of that company. Priced in U.S. dollars, these ADR shares trade just ...

Bristol-Myers Squibb Company (BMY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.46, which comfortably ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Bain Capital and Bristol Myers Squibb are providing financial and scientific support to a new startup working on autoimmune ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company (NewCo) focused on developing new therapies for autoimmune diseases that ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, the ...